Abstract

Currently, the assessment of the immunogenic properties of influenza viruses as a part of influenza vaccines is carried out by using seroprotection, seroconversion as well as the rate of increases in post-vaccination antibodies. At the same time, significant differences in the immunogenicity of vaccines related to dynamic formation of high antibody titers responsible for long-term protection of the vaccinated, are neglected. Influenza viruses such as A(H1N1)pdm09 that caused 2009–2010 pandemic continue to circulate in the population, therefore, the assessment of the immunogenic activity of vaccine viruses prepared during the pandemic period is interesting in for the methodology to prepare pandemic vaccines to be used in various groups (adults, children, elderly people). Analyzing immunogenicity of influenza vaccines used during the 2009–2010 swine influenza pandemic and the post-pandemic period up to the year 2014 was carried out by applying the graphical method for assessing immunogenicity (immunographs) measured as follows: for each group of vaccinated subjects (depending on the vaccine used), an increased rate in antibody level was calculated and the graphs of immunogenicity were plotted. An increased rate of serum antibodies magnitude from vaccinated subjects and the number of sera (in %) with a given fold increase rate in antibody level from 1 to the maximum magnitude were plotted on the x- and y-axis, respectively. The proposed method for assessing immunogenicity allows to plot immunogenicity graphs regardless of the serum antibodies level found in volunteers. The assessment described above revealed a several features for developing immune response to the pandemic virus A(H1N1)pdm09 such as the lack of immune response in a substantial number of adult volunteers (25–27%) and young children (60–70%) after monovaccine administration. The reason for such immune response can be both an insufficient dose of vaccine-containing viral antigen and suppressed immune response caused by the influenza A(H1N1)pdm09. A study on the immunogenic properties for seasonal influenza vaccines containing the influenza A(H1N1)pdm09 virus antigen in the years 2010–2014 revealed a variety in emerging humoral immunity ranging from a short-term, low-frequency increase in antibodies from vaccinated children to the formation of high antibody titers in elderly. Practically, immunographic analysis of influenza vaccines particularly those derived from the influenza A(H1N1)pdm09 virus, may result in proposing recommendations to increase an antigenic load at the beginning of a pandemic cycle and/or block the suppressive properties of vaccine-contained viruses in pediatric vaccines, because escalating virus dose in the vaccine may not always be achievable in this case.

Highlights

  • Significant differences in the immunogenicity of vaccines related to dynamic formation of high antibody titers responsible for longterm protection of the vaccinated, are neglected

  • Influenza viruses such as A (H1N1) pdm09 that caused 2009-2010 pandemic continue to circulate in the population, the assessment of the

  • Analyzing immunogenicity of influenza vaccines used during the 2009-10 swine influenza pandemic and the post-pandemic period up to the year 2014 was carried out by applying the graphical method for assessing immunogenicity measured as follows: for each group of vaccinated subjects, an increased rate in antibody level was calculated and the graphs of immunogenicity were plotted

Read more

Summary

15 Использование динамического показателя кратности нарастания антител

популяции, поэтому оценка иммуногенной активности вакцинных вирусов, подготовленных в пандемический период, представляет интерес с точки. 27 различных коллективах (взрослые, дети, пожилые люди)

64 Все вакцины были зарегистрированы на территории РФ и допущены к
Findings
88 Определение иммунногенной активности вакцинного штамма вируса гриппа
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call